Structure-Guided Design of Novel Diarylpyrimidine-Based NNRTIs Through a Comprehensive In Silico Approach: 3D-QSAR, ADMET Evaluation, Molecular Docking, and Molecular Dynamics
Pharmaceuticals · 05.12.2025 · 18 (12) · 1854
DOI: 10.3390/ph18121854 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 05.12.2025. Verfasst von Mouna Baassi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Physical Chemistry of Applied Materials (LCPMA), Faculty of Sciences Ben M'Sick, Hassan II University of Casablanca, Casablanca 20670, …. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: The emergence of drug-resistant HIV-1 strains challenges the long-term efficacy of current antiretroviral therapies. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are critical in HIV-1 treatment; however, the need for new candidates with improved resistance profiles and pharmacokinetics remains. This study aims to design and evaluate novel NNRTIs targeting both wild-type (WT) and mutant-type (MT) HIV-1 reverse transcriptase (RT) using integrated computational strategies.
Methods
We conducted a 3D-QSAR study on 33 naphthyl-diarylpyrimidine derivatives using CoMFA and CoMSIA models. We designed thirty-five novel molecules based on contour map insights. We applied ADMET and drug-likeness filters to prioritize ten candidates. Molecular docking was performed on WT (PDB: 3HVT) and MT (PDB: 4PUO) RT structures. The top candidates underwent 100 ns molecular dynamics (MD) simulations. We analyzed structural stability via RMSD, RMSF, and Rg, while we used SASA and MolSA to assess solvent exposure and surface compactness.
Results
The CoMFA and CoMSIA models demonstrated robust predictivity (R2 = 0.979/0.920, Q2 = 0.643/0.546, R2test = 0.747/0.603). P14 and P43 showed higher binding affinities than nevirapine and favorable ADMET profiles. MD simulations confirmed stable binding in WT-RT and adaptive flexibility in MT-RT. SASA and MolSA analysis revealed favorable conformational compaction. Drug-likeness profiles indicated optimal log P, strong hydrogen bonding, and acceptable bioavailability.
Conclusions
P14 and P43 demonstrate strong potential as NNRTI leads, combining binding affinity, structural stability, and favorable pharmacokinetics, supporting further experimental development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Physical Chemistry of Applied Materials (LCPMA), Faculty of Sciences Ben M'Sick, Hassan II University of Casablanca, Casablanca 20670, Morocco.
- Chemical and Biochemical Sciences-Green Processing Engineering, Mohammed VI Polytechnic University, Ben Guerir 43150, Morocco.
- Centre of Biotechnology and Bioinformatics, Dibrugarh University, Dibrugarh 786004, Assam, India.
ORCID-Profile: Mouna Baassi, Mohamed Moussaoui, Sanchaita Rajkhowa
Zitieren
APA
Baassi, M., Moussaoui, M., Rajkhowa, S., Soufi, H., Daoud, R., & Belaaouad, S. (2025). Structure-Guided Design of Novel Diarylpyrimidine-Based NNRTIs Through a Comprehensive In Silico Approach: 3D-QSAR, ADMET Evaluation, Molecular Docking, and Molecular Dynamics. Pharmaceuticals, 18(12), 1854. https://doi.org/10.3390/ph18121854
Vancouver
Baassi M, Moussaoui M, Rajkhowa S, Soufi H, Daoud R, Belaaouad S. Structure-Guided Design of Novel Diarylpyrimidine-Based NNRTIs Through a Comprehensive In Silico Approach: 3D-QSAR, ADMET Evaluation, Molecular Docking, and Molecular Dynamics. Pharmaceuticals. 2025;18(12):1854. doi:10.3390/ph18121854
BibTeX
@article{Baassi2025,
author = {Baassi, Mouna and Moussaoui, Mohamed and Rajkhowa, Sanchaita and Soufi, Hatim and Daoud, Rachid and Belaaouad, Said},
title = {Structure-Guided Design of Novel Diarylpyrimidine-Based NNRTIs Through a Comprehensive In Silico Approach: 3D-QSAR, ADMET Evaluation, Molecular Docking, and Molecular Dynamics},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {12},
pages = {1854},
doi = {10.3390/ph18121854}
}
EUVIMED